Wellmarker Bio, a company specialized in predictive biomarker-based novel anti-cancer drug development was founded in 2016 with professor Dong-Hoon Jin’s(CEO of WMBIO) motivation to provide individualized treatments to patients with unmet medical needs. While serving as a Chief of Drug Discovery Support Center at Asan Medical Center, he found that majority of the patients experience devastating financial hardship and felt the necessity to develop effective anticancer drugs that are less toxic and costly.
The company is now developing 9 patient-oriented anticancer drugs based on the patients’ predictive biomarkers and it is planning an initial public offering (IPO) with the aim to become a global top 50 biopharmaceutical company in the next decades.
Please click on the link below to read the full interview in Korean.
The company is now developing 9 patient-oriented anticancer drugs based on the patients’ predictive biomarkers and it is planning an initial public offering (IPO) with the aim to become a global top 50 biopharmaceutical company in the next decades.
Please click on the link below to read the full interview in Korean.